OrbusNeich launches new Dual Therapy Stent for active vessel healing

OrbusNeich has announced the launch of its latest generation Dual Therapy Stent (DTS), the COMBO Plus. The COMBO Plus has a unique anti-CD34 antibody biological coating that offers an advanced approach to active vessel healing combined with improved deliverability for patients with complex coronary artery disease.

Multiple design features make COMBO Plus a unique and effective option for treating coronary stenosis. Following implantation, the biological coating on the outer surface of the COMBO Plus immediately captures endothelial progenitor cells and initiates the formation of an endothelial layer. This accelerated healing process, leads to earlier return of functionality and may reduce adverse events in the long-term. In concert with the biological layer, a directional coating of bioabsorbable polymer elutes sirolimus to inhibit neointimal hyperplasia.

COMBO Plus employs an enhanced balloon catheter with a lower profile design, lubricious coating and reduced shaft diameters for superior deliverability. The stent design is based on OrbusNeich's R-Stent pattern, which has proven to impart strength and stability during expansion without sacrificing conformability.

"Our design improvements provide superior deliverability and powerful performance for complex daily practice," said David Chien, Chairman of the Board. "COMBO Plus offers physicians a compelling new treatment option for patients with coronary artery disease."

A long-time leader in coronary artery disease treatment, in 2013 OrbusNeich launched the innovative COMBO Dual Therapy Stent, the world's first dual therapy stent to accelerate endothelial coverage and control neointimal proliferation through the combination of the proven Pro-Healing Technology with an abluminal sirolimus drug elution delivered from a bioresorbable polymer that is completely dissipated within 90 days. COMBO is supported by clinical evidence from the REMEDEE family of studies and several other investigator-initiated studies, totaling over 6,000 patients enrolled across more than 26 countries.

Source: OrbusNeich

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
ELISA and CLIA antibody tests for SARS-CoV-2 perform best in terms of sensitivity